Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014

- Conference Call and Webcast to Follow -

Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Exelixis, Inc. (EXEL) will release its first quarter 2014 financial results on Thursday, May 1, 2014 after the markets close. The announcement will be followed by a live conference call and webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the presentation, Exelixis management will discuss the Company's financial results and provide a general business update.

The conference call will be webcast live and may be accessed in the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-866-202-3048 (domestic) or 1-617-213-8843 (international) and provide the conference call passcode 28848437 to join by phone.

A telephone replay will be available until 11:59 p.m. PDT on June 1, 2014. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 74388407. A webcast replay will also be archived on www.exelixis.com for 30 days.

About Exelixis

Exelixis is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ® (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.

Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.

Contact:
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor Relations and Corporate Communications
shubbard@exelixis.com

Rates

View Comments (0)